Liraglutide

## What Liraglutide Is

Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone that plays a central role in glucose homeostasis and appetite regulation. The FDA approved liraglutide in 2010 under the brand name Victoza (1.8 mg daily dose) for the treatment of type 2 diabetes mellitus in adults, and in 2014 under the brand name Saxenda (3.0 mg daily dose) for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbid condition such as hypertension, dyslipidemia, or type 2 diabetes.

Unlike semaglutide and tirzepatide, which are typically administered once weekly, liraglutide requires daily subcutaneous injection. It has approximately 97% amino acid sequence homology to native human GLP-1 but includes modifications that extend its half-life to approximately 13 hours, allowing for once-daily dosing.

## Mechanism of Action

Liraglutide binds to and activates the GLP-1 receptor, which is expressed in multiple tissues including pancreatic beta cells, the gastrointestinal tract, and regions of the brain involved in appetite regulation. Activation of this receptor produces several metabolic effects:

- **Glucose-dependent insulin secretion:** Liraglutide enhances insulin release from pancreatic beta cells only when blood glucose levels are elevated, reducing the risk of hypoglycemia compared to insulin or sulfonylureas. - **Suppression of glucagon:** It reduces glucagon secretion from pancreatic alpha cells, decreasing hepatic glucose production. - **Delayed gastric emptying:** Liraglutide slows the rate at which food leaves the stomach, contributing to prolonged satiety and reduced postprandial glucose excursions. - **Central appetite suppression:** GLP-1 receptors in the hypothalamus and brainstem mediate reduced hunger and food intake.

These combined effects result in improved glycemic control in individuals with type 2 diabetes and modest weight reduction in individuals treated for obesity.

## Clinical Evidence and Efficacy

The efficacy of liraglutide for weight management was established in the SCALE (Satiety and Clinical Adiposity—Liraglutide Evidence) clinical trial program. The pivotal SCALE Obesity and Prediabetes trial, published in *The New England Journal of Medicine* in 2015 (PMID: 26132939), enrolled 3,731 adults without diabetes who were randomized to receive liraglutide 3.0 mg daily or placebo, both combined with lifestyle intervention. After 56 weeks, participants on liraglutide lost an average of 8.4 kg (8.0% of baseline body weight) compared to 2.8 kg (2.6%) in the placebo group. Approximately 63% of liraglutide-treated participants achieved at least 5% weight loss, compared to 27% in the placebo group.

For glycemic control in type 2 diabetes, the LEAD (Liraglutide Effect and Action in Diabetes) trial series demonstrated significant reductions in hemoglobin A1c (HbA1c) ranging from 0.8% to 1.5% depending on baseline glycemic control and concomitant therapies. A 2012 meta-analysis published in *The Lancet* (PMID: 22607825) concluded that liraglutide at 1.8 mg daily was associated with greater HbA1c reduction and weight loss compared to other GLP-1 receptor agonists available at the time.

## Regulatory Status and Compounded Liraglutide

Branded liraglutide products—Victoza and Saxenda—carry FDA approval for their labeled indications. However, compounded liraglutide formulations are not FDA-approved drug products. Compounded medications are prepared by state-licensed pharmacies in response to an individual prescription and are not subject to the same premarket approval process as commercially manufactured drugs. The FDA does not evaluate compounded drugs for safety, efficacy, or quality prior to dispensing.

Patients considering compounded liraglutide through a telehealth service like ZYNDIO should understand that these formulations may differ in concentration, excipients, or delivery device from the branded versions. A licensed healthcare provider must evaluate the patient's medical history, contraindications, and appropriateness for therapy before prescribing any form of liraglutide.

## Who May Be a Candidate

Liraglutide for weight management (Saxenda) is typically considered for adults with:

- A BMI of 30 kg/m² or greater (obesity), OR - A BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidemia

Liraglutide is not indicated for type 1 diabetes or diabetic ketoacidosis. It should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as GLP-1 receptor agonists have been associated with thyroid C-cell tumors in rodent studies.

Other contraindications and precautions include:

- Hypersensitivity to liraglutide or any excipient - History of pancreatitis - Severe gastroparesis or gastrointestinal disease - Pregnancy or breastfeeding (liraglutide is not recommended during pregnancy)

## Common and Serious Side Effects

The most frequently reported side effects of liraglutide are gastrointestinal and include:

- Nausea (most common, particularly during dose escalation) - Vomiting - Diarrhea - Constipation - Abdominal pain

These symptoms are typically transient and improve as the body adjusts to the medication. Dose titration—starting at 0.6 mg daily and increasing by 0.6 mg weekly intervals up to the target dose—can help minimize gastrointestinal side effects.

Serious but less common adverse events include:

- **Pancreatitis:** Acute pancreatitis has been reported in postmarketing surveillance. Patients should be counseled to discontinue liraglutide and seek medical attention if they experience severe abdominal pain. - **Gallbladder disease:** Increased risk of cholelithiasis (gallstones) and cholecystitis has been observed with GLP-1 receptor agonists, likely related to rapid weight loss. - **Hypoglycemia:** Risk is low when liraglutide is used alone but increases when combined with insulin or sulfonylureas. Dose adjustment of concomitant medications may be necessary. - **Renal impairment:** Gastrointestinal side effects leading to dehydration may exacerbate renal dysfunction, particularly in patients with pre-existing kidney disease. - **Thyroid C-cell tumors:** Based on rodent data, liraglutide carries a boxed warning regarding the potential risk of thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of MTC or MEN 2. - **Suicidal ideation:** As with other weight-loss medications, patients should be monitored for depression or suicidal thoughts.

## What to Expect From a Telehealth Consultation

If you are considering liraglutide through a telehealth service like ZYNDIO, the consultation will typically involve:

- A comprehensive review of your medical history, including current medications, allergies, and prior weight-loss attempts - Assessment of contraindications, such as personal or family history of thyroid cancer, history of pancreatitis, or active gallbladder disease - Evaluation of your BMI, weight-related comorbidities, and overall candidacy for GLP-1 therapy - Discussion of expectations, including realistic weight-loss goals, the importance of lifestyle modification, and potential side effects - Prescription of an appropriate starting dose (typically 0.6 mg daily) with instructions for weekly titration - Guidance on injection technique, proper storage of the medication, and follow-up monitoring

The licensed provider—not ZYNDIO—makes all clinical decisions regarding whether liraglutide is appropriate for you. If prescribed, the medication is dispensed by a state-licensed compounding pharmacy and shipped to your address.

## Monitoring and Follow-Up

Patients on liraglutide should be monitored regularly for:

- Weight loss progress and adherence to lifestyle modifications - Blood glucose levels (if used for type 2 diabetes) - Gastrointestinal tolerability - Signs of pancreatitis (severe abdominal pain) - Renal function, particularly in patients with pre-existing kidney disease or those experiencing significant gastrointestinal side effects - Blood pressure and heart rate (liraglutide can cause a modest increase in resting heart rate)

Routine follow-up with a healthcare provider is essential to assess efficacy, manage side effects, and determine the appropriate duration of therapy. Weight-loss medications are not intended for indefinite use without periodic reassessment.

## Liraglutide vs. Other GLP-1 Receptor Agonists

Liraglutide is one of several GLP-1 receptor agonists available for weight management and glycemic control. Key differences include:

| Feature | Liraglutide (Saxenda) | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | |---------|----------------------|---------------------|------------------------| | Dosing frequency | Daily | Weekly | Weekly | | Average weight loss (vs. placebo) | ~8% at 56 weeks | ~15% at 68 weeks | ~20% at 72 weeks | | FDA approval for weight loss | 2014 | 2021 | 2023 | | Mechanism | GLP-1 agonist | GLP-1 agonist | Dual GIP/GLP-1 agonist |

Weekly GLP-1 agonists like semaglutide and tirzepatide have demonstrated greater weight loss in head-to-head and indirect comparisons, but daily liraglutide may be preferred by some patients due to more granular dose control or prior experience with the medication.

## **Medical Disclaimer**

The information in this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. ZYNDIO connects adults with licensed providers via telehealth; the providers—not ZYNDIO—make all clinical decisions. Compounded medications dispensed through ZYNDIO partners are not FDA-approved drug products. They are prepared by state-licensed compounding pharmacies pursuant to a valid prescription. Individual results vary. Side effects, drug interactions, and contraindications exist for every therapy discussed here.

Last reviewed: 2026-04-25 by ZYNDIO Clinical Editorial Team (PharmD-led)

## FAQ

**Is liraglutide the same as Ozempic?**

No. Liraglutide and semaglutide (the active ingredient in Ozempic and Wegovy) are both GLP-1 receptor agonists, but they are different molecules with different dosing schedules. Liraglutide is administered daily, while semaglutide is administered weekly. Clinical trial data suggest semaglutide produces greater weight loss on average, but liraglutide remains an effective option and was the first GLP-1 receptor agonist to receive FDA approval for chronic weight management.

**How long does it take to see weight loss on liraglutide?**

Most patients begin to see weight loss within the first 4-8 weeks of therapy, particularly as the dose is titrated upward. Maximum weight loss typically occurs between 24 and 56 weeks of continuous treatment combined with lifestyle modification. Individual results vary significantly based on adherence, baseline BMI, diet, and physical activity.

**Can I take liraglutide if I don't have diabetes?**

Yes. Liraglutide at the 3.0 mg dose (Saxenda) received FDA approval specifically for chronic weight management in adults without diabetes who meet BMI criteria. It is not necessary to have type 2 diabetes to be a candidate for liraglutide for weight loss, though your provider will evaluate your full medical history to determine appropriateness.

**What happens if I miss a dose of liraglutide?**

If you miss a dose and it has been less than 12 hours since your usual injection time, take the missed dose as soon as you remember. If more than 12 hours have passed, skip the missed dose and resume your regular schedule the following day. Do not double up on doses. Consistent daily dosing is important for maintaining stable blood levels and minimizing side effects.

**Is compounded liraglutide safe?**

Compounded liraglutide is not an FDA-approved drug product and has not been evaluated by the FDA for safety, efficacy, or quality. Compounded medications are prepared by state-licensed pharmacies in response to an individual prescription and must meet state pharmacy board standards. Patients should discuss the risks and benefits of compounded formulations with a licensed healthcare provider and ensure they are obtaining medication from a reputable, licensed compounding pharmacy.